Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Pharmacodynamics
- 05 Dec 2017 Planned primary completion date changed from 12 Jun 2017 to 6 Aug 2018.
- 01 Dec 2017 Planned number of patients changed from 42 to 24.
- 01 Dec 2017 Planned End Date changed from 6 Aug 2017 to 6 Aug 2018.